A 46-year-old woman had an episode of atrial fibrillation during infusion of docetaxel as adjuvant chemotherapy for an infiltrating ductal carcinoma of the breast. All cardiological tests performed before treatment were normal and there was no evidence of thyroid dysfunction nor any objective or anamnestic data indicating acute or chronic cardiovascular disease. None of the drugs administered has ever shown any proarrhythmic activity. In controlled clinical trials docetaxel was found to have a very low cardiotoxicity.
HudisC.: Chemotherapy for early-stage breast cancer. Am Soc Clin Oncol Educational Book: 266–273, 2000.
2.
ViensP., KerbratP., FumoleauP., GuastallaJ.P., RocheH., DelozierT., MarcillacI., BardonnetM.: Epirubicin in combination with docetaxel as first-line chemotherapy of metastatic breast cancer: preliminary results of phase I dose finding study. Proc ASCO, 16: 690A, 1997.
3.
RossoR., PalmieriS., Tamburo De BellaM., GridelliC.: Meccanismo d'azione; farmacocinetica e metabolismo; studi di fase I. In: Docetaxel: farmacologia e clinica, RossoR. (ed), pp 3–8, 69–74, 91–101, Mosby Italia, Milano, 1998.
4.
CazapE., VentrigliaE., RubioG., EstevezR.: Taxol plus doxorubicin in the treatment of metastatic breast cancer ambulatory patients. Proc ASCO, 15: 248A, 1996.
5.
DombernowskyP., GehlJ., BoesgaardM., PaaskeT., JensenB.V.: Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer. Semin Oncol, 23(suppl 11): 23–27, 1996.
6.
FrassinetiG.L., ZoliW., SilvestroL., SerraP., MilandriC., TienghiA., GianniL., GentileA., SalzanoE., AmadoriD.: Paclitaxel plus doxorubicin in breast cancer: an Italian experience. Semin Oncol, 24(suppl 17): S17–25, 1997.
7.
GehlJ., BoesgaardM., PaaskeT., Vittrup JensenB., DombernowskyP.: Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Ann Oncol, 7: 687–693, 1996.
8.
GianniL., MunzoneE., CapriG., FulfaroF., TarenziE., VillaniF., SpreaficoC., LaffranchiA., CaraceniA., MartiniC.: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol, 13: 2688–2699, 1995.
9.
GianniL., CapriG., TarenziE., FulfaroF., VillaniF., ValagussaP., BonadonnaG.: Efficacy and cardiac effects of 3-hour paclitaxel plus bolus doxorubicin in women with untreated metastatic breast carcinoma. Proc ASCO, 15: 128A, 1996.
10.
SledgeG.W.Jr., NeubergD., IngleJ., WoodW.: Phase III trial of doxorubicin versus paclitaxel as first-line therapy for metastatic breast cancer: an intergroup trial. Proc ASCO, 16: 2A, 1997.
11.
SchwartsmannG., MenkeC.H., CaleffiM., XavierN., Ferreira FilhoA.F., SchunemannH., KoyaR., StrodaP.R., PohlmannP., VenegasL.F., KalakunL.: Phase II trail of taxol, doxorubicin plus G-CSF in patients with metastatic breast cancer. Proc ASCO, 15: 168A, 1996.
12.
SparanoJ.A., HuP., RaoR.M., FalksonC.I., WolffA.C., WoodW.C.: Phase II trial of doxorubicin plus paclitaxel plus G-CSF in metastatic breast cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol, 17: 3828–3834, 1999.
13.
SparanoJ.A., SpeyerJ., GradisharW.: Phase I trial of zinecard, adriamycin, and escalating doses of taxol in advanced breast cancer (T95-0054). Breast Cancer Res Treat, 46: 56, 1997.
14.
AaproM.S.: Combining new agents with anthracyclines in metastatic breast cancer: an overview of recent findings. Semin Oncol, 26(suppl 3): 17–21, 1999.
15.
DierasV.: Docetaxel in combination with doxorubicin: a phase I dose-finding study. Oncology, 11(suppl 6): 7–20, 1997.
16.
DierasV.: Taxanes in combination with doxorubicin in the treatment of metastatic breast cancer. Semin Oncol, 25(Suppl 12): 18–22, 1998.
17.
DierasV., BarthierS., BeuzebocP.: Phase II study of docetaxel in combination with doxorubicin as 1st line chemotherapy of metastatic breast cancer. Breast Cancer Res Treat, 50: 262, 1998.
18.
ItohK., FujiiH., MinamiH., OhtsuT., WakitaH., IgarashiT., SasakiY., KashimuraM.: Phase I and pharmacological study of docetaxel combined with doxorubicin for advanced breast cancer. Proc ASCO, 16: 610A, 1997.
19.
KennedyM.J., ElzaK., DonehowerR.: Phase I and pharmacologic study of docetaxel and doxorubicin in patients with solid tumors: dose limiting toxicity at the first dose level. Proc ASCO, 16: 845A, 1997.
20.
MissetJ.L., DierasV., Bozec, BoutgeoisH., GruiaG., KallaS., GiacchettiS., CvitkovicE., AusseiJ., AzliN., RivaA., PouillartP.: Long term follow up of the phase I/II study of docetaxel and doxorubicin as 1st line chemotherapy of metastatic breast cancer. Proc ASCO, 17: 613A, 1998.
21.
NabholtzJ.M., SmylieM., MackeyJ.R., NoelD., PatersonA.H., al-TweigeriT., AuD., SansregretE., DelormeF., RivaA.: Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer. Oncology, 11(Suppl 8): 37–41, 1997.
22.
NabholtzJ.M., MackeyJ.R., SmylieM., PatersonA., NoelD., al-TweigeriT., DelormeF., RivaA.: Phase II study of taxotere (docetaxel), doxorubicin and cyclophosphamide (TAC) in the treatment of metastatic breast cancer. Proc ASCO, 16: 518A, 1997.
23.
NabholtzJ.M., MackeyJ.R., SmylieM.: Final results of a phase II study of docetaxel, doxorubicin and cyclophosphamide (TAC) as first-line chemotherapy in metastatic breast cancer patients. Breast Cancer Res Treat, 50: 27, 1998.
24.
NabholtzJ.M., FalksonG., Campos, SzantoJ., MartinM., ChanS., PienkowkiT., BezwodaW.R., ZahiskiJ., PinterT., KrzakowskiM., VorobiefD., LeonardR., KennedyI., AzliN., MurawskiM., RivaA., PouillortP.on behalf of the International TAX 306 Study Group: A phase III trial comparing doxorubicin and docetaxel to doxorubicin and cyclophosphamide as first line chemotherapy for metastatic breast cancer. Proc ASCO, 18: 127, 485A, 1999.
25.
NabholtzJ.M., SmylieM., MackeyJ., AuH.J., TonkinK., MorrishD., SalterE.: Docetaxel and anthracycline polychemotherapy in the treatment of breast cancer. Semin Oncol, 26(Suppl 8): 47–52, 1999.
26.
NabholtzJ.M., NorthS., SmylieM., MackeyJ., AuH.J., AuR., MorrisD., SalterE., TonkinK.: Docetaxel (Taxotere) in combination with anthracyclines in the treatment of breast cancer. Semin Oncol:27(Suppl 3): 11–18, 2000.
27.
PaganiO.: Taxoids in combination with epirubicin: the search for improved outcomes in breast cancer. Semin Oncol, 25(Suppl 12): 23–26, 1998.
28.
SparanoJ.A., SmylieM., MackeyJ., PatersonA., NoelD., al-TweigeriT., JanowskaA., DelormeF., RivaA.: Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer. Oncology, 11(Suppl 6): 25–27, 1997.
29.
SparanoJ.A., JuP., ScheaferP.L.: Phase II trial of doxorubicin and docetaxel plus granulocyte-colony stimulating factor in metastatic breast cancer: An Eastern Cooperative Oncology Group Study (E1196). Breast Cancer Res Treat, 50: 27, 1998.
D'IncalciM., SchüllerJ., ColomboT., ZucchettiM., RivaA.: Taxoids in combination with antracyclines and other agents: pharmacokinetic considerations. Semin Oncol, 25(Suppl 13): 16–20, 1998.
32.
MinottiG., SaponieroA., LicataS., MennaP., CalafioreA.M., TeodoriG., GianniL.: Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium. Clin Cancer Res, 7: 1511–1515, 2001.
33.
BissettD., SetanoiansA., CassidyJ., GrahamM.A., ChadwickG.A., WilsonP., AuzannetV., Le BailN., KayeS.B., KerrD.J.: Phase I and pharmacokinetic study of Taxotere (RP 56976) administered as a 24-hour infusion. Cancer Res, 53: 523–527, 1993.
34.
CrownJ.P., DonnellanP., SullivanC., RowanS., JonesM., ChanK.M., DuffyK., O'LearyM., BreathnachO., MoultonB.C., MacErleanD., SchranceM., MurrayR., NuttyS., FlynnC., FennellyD., MoriartyM., O'NeillS., LynchV., NicholasW., GallagherC., ArmstrongJ.: Phase I/II evaluation of escalating dose docetaxel, ifosfamide and cisplatin with lenograstim support, in patients with stage III/IV NSCLC: an Irish Clinical Oncology Research Group (ICORG). Proc ASCO, 18: 1840A, 1999.
35.
GobB.C., WangT.L., WongJ., LimH.L., LinJ., KongH.L., LeeS.C.: Phase II trial of docetaxel (Taxotere) in inoperable stage III NSCLC. Proc ASCO, 16: 1686A, 1997.
36.
CrestaS., GrasselliG., MartoniG., LelliM., ManzuttiM., CapriG., BuzziF., RobustelliG., FrevolaL., MekhaldiS., AzliN., GianniL.: A randomized phase II study of alternating (AA) vs sequential (SS) vs the combination (CC) of doxorubicin (A) and docetaxel (T) as 1st line CT in MBC pts. Proc ASCO, 20: 190A, 2001.
